274 related articles for article (PubMed ID: 27340238)
21. [Molecular biological diagnostics of KRAS and BRAF mutations in patients with colorectal cancer - laboratory experience].
Robešová B; Bajerová M; Vašíková A; Ostřížková L; Hausnerová J; Kyclová J; Pospíšilová S; Mayer J; Dvořáková D
Klin Onkol; 2013; 26(1):25-30. PubMed ID: 23528169
[TBL] [Abstract][Full Text] [Related]
22. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
23. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
24. Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients.
Nakayama I; Shinozaki E; Matsushima T; Wakatsuki T; Ogura M; Ichimura T; Ozaka M; Takahari D; Suenaga M; Chin K; Mizunuma N; Yamaguchi K
BMC Cancer; 2017 Jan; 17(1):38. PubMed ID: 28068936
[TBL] [Abstract][Full Text] [Related]
25. BRAF V600E Mutant Colorectal Cancer Subtypes Based on Gene Expression.
Barras D; Missiaglia E; Wirapati P; Sieber OM; Jorissen RN; Love C; Molloy PL; Jones IT; McLaughlin S; Gibbs P; Guinney J; Simon IM; Roth AD; Bosman FT; Tejpar S; Delorenzi M
Clin Cancer Res; 2017 Jan; 23(1):104-115. PubMed ID: 27354468
[TBL] [Abstract][Full Text] [Related]
26. The prognostic role of microsatellite instability, codon-specific KRAS, and BRAF mutations in colon cancer.
Lin CC; Lin JK; Lin TC; Chen WS; Yang SH; Wang HS; Lan YT; Jiang JK; Yang MH; Chang SC
J Surg Oncol; 2014 Sep; 110(4):451-7. PubMed ID: 24964758
[TBL] [Abstract][Full Text] [Related]
27. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
28. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
29. Mutation pattern of KRAS and BRAF oncogenes in colorectal cancer patients.
Rako I; Jakic-Razumovic J; Katalinic D; Sertic J; Plestina S
Neoplasma; 2012; 59(4):376-83. PubMed ID: 22489692
[TBL] [Abstract][Full Text] [Related]
30. [Detection of KRAS, BRAF, PIK3CA and EGFR gene mutations in colorectal carcinoma].
Ling Y; Ying JM; Qiu T; Shan L; Guo L; Lü N
Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):590-4. PubMed ID: 23157825
[TBL] [Abstract][Full Text] [Related]
31. Evaluation and identification of factors related to
Lin L; Chen GY; Xu CW; Wang HY; Wu YF; Fang MY
J Cancer Res Ther; 2016 Dec; 12(Supplement):C191-C198. PubMed ID: 28230016
[TBL] [Abstract][Full Text] [Related]
32. Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines.
Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
Metabolomics; 2021 Nov; 17(12):104. PubMed ID: 34822010
[TBL] [Abstract][Full Text] [Related]
33. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
[TBL] [Abstract][Full Text] [Related]
34. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability.
Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T
J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994
[TBL] [Abstract][Full Text] [Related]
35. Distribution of KRAS and BRAF mutations in Moroccan patients with advanced colorectal cancer.
Marchoudi N; Amrani Hassani Joutei H; Jouali F; Fekkak J; Rhaissi H
Pathol Biol (Paris); 2013 Dec; 61(6):273-6. PubMed ID: 23849768
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemistry with Anti-BRAF V600E (VE1) Mouse Monoclonal Antibody is a Sensitive Method for Detection of the BRAF V600E Mutation in Colon Cancer: Evaluation of 120 Cases with and without KRAS Mutation and Literature Review.
Dvorak K; Higgins A; Palting J; Cohen M; Brunhoeber P
Pathol Oncol Res; 2019 Jan; 25(1):349-359. PubMed ID: 29127628
[TBL] [Abstract][Full Text] [Related]
37. BRAF, PIK3CA, and HER2 Oncogenic Alterations According to KRAS Mutation Status in Advanced Colorectal Cancers with Distant Metastasis.
Nam SK; Yun S; Koh J; Kwak Y; Seo AN; Park KU; Kim DW; Kang SB; Kim WH; Lee HS
PLoS One; 2016; 11(3):e0151865. PubMed ID: 26991109
[TBL] [Abstract][Full Text] [Related]
38. Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.
Kosmidou V; Oikonomou E; Vlassi M; Avlonitis S; Katseli A; Tsipras I; Mourtzoukou D; Kontogeorgos G; Zografos G; Pintzas A
Hum Mutat; 2014 Mar; 35(3):329-40. PubMed ID: 24352906
[TBL] [Abstract][Full Text] [Related]
39. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
40. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
